In this study, we examined whether exogenous b 2 -microglobulin (b 2 m) can induce apoptosis in the drug sensitive HL-60 leukemia cell line and its drug resistant variants and investigated the molecular mechanism of b 2 m-induced apoptosis. Our data revealed that b 2 m is very signi®cantly down-regulated in two multidrug resistant variants of the HL-60 cells: (a) the MRP1-bearing, Bax-de®cient HL-60/ADR cell line, and (b) the P-glycoprotein (P-gp) overexpressing HL-60/VCR cell line. However, exogenous b 2 m induced similar levels of apoptosis in HL-60 cells and these drug resistant variants. b 2 m-induced apoptosis in HL-60 and HL-60/ VCR cells was associated with decreased mitochondrial membrane potential (Dcm) but did not aect Dcm in HL-60/ADR cells. Surprisingly, cyclosporin A (CsA), a known inhibitor of the mitochondrial permeability transition (MPT) pore, inhibited b 2 m-induced apoptosis in HL-60/ADR cells but not in HL-60 and HL-60/VCR cells, suggesting that the pro-apoptotic eect of b 2 m in these cells is not through MPT pore formation. Furthermore, b 2 m induced the release of cytochrome c and the apoptosis-inducing factor (AIF) from mitochondria in HL-60 and HL-60/VCR cells, but not in HL-60/ ADR cells. Additionally, Z-VAD-fmk, a general inhibitor of caspases which inhibited cytochrome c release in HL-60 and HL-60/VCR cells, had no eect on AIF release in any of these cell lines, but inhibited b 2 m-induced apoptosis in all three cell lines. However, Western blot analysis revealed that caspases-1, -3, -6, -8, and -9 are not activated during b 2 m-induced apoptosis in these cells. Therefore, b 2 m-induces apoptosis through an unknown caspase-dependent mitochondrial pathway in HL-60 and HL-60/VCR cells and by a Bax-independent, nonmitochodrial, caspase-dependent pathway in HL-60/ ADR cells. Oncogene (2001) 20, 7006 ± 7020.
Introduction
Major histocompatibility complex class I (MHC class I) presents proteasome-generated antigens to cytotoxic CD8 + T-cells, is generally found on the surface of most normal cells (Dixon et al., 1993) , and regulates cellular and humoral immunities, as well as tumor immunity (Ploegh et al., 1981; Parham and Ohta, 1996) . MHC class I or HLA class I consist of two polypeptide chains: a 45 kDa heavy chain (HC) consisting of a cytoplasmic region, a transmembrane region and an extracellular region consisting of three domains with N-linked glycosylation sites, and a 12 kDa chain (extracellular light chain) referred to as b 2 -microglobulin (b 2 m) (D'Urso et al., 1991; Dixon et al., 1993) . b 2 m is a non-glycosylated protein with no transmembrane domain and usually associates with cells by interacting with the extracellular region of the heavy chain.
Defects in the MHC class I antigen-processing machinery may provide malignant cells with a mechanism to escape immune surveillance and as a result create a negative impact on the outcome of Tcell-based immunotherapy. Several studies have described down-regulation of MHC class I in a number of tumor specimens, including melanoma, breast, cervical and colorectal cancers, small cell lung cancer (SCLC) cell lines, Burkitt's lymphoma, prostate carcinoma and renal cell carcinoma cell lines (Restifo et al., 1993; Kaklamanis et al., 1995; Chen et al., 1996; Vitale et al., 1998) .
In addition to their role in antigen presentation and natural killer cell activity regulation, MHC class I molecules may also be involved in signal transduction, T-cell activation, cell proliferation and apoptosis (Genestier et al., 1997a,b; Skov et al., 1997a; Wallen-Ohman et al., 1997) . The intracellular signaling events after MHC class I ligation include protein tyrosine phosphorylation and increased cellular free calcium (Skov et al., 1997a) . Evidence suggests that ligation of MHC class I molecules on human T-cells induces apoptosis through PI-3 kinase-induced c-Jun NH 2 -terminal kinase (JNK) activity (Skov et al., 1997b) . Recent reports indicate that monoclonal antibodies recognizing speci®c domains on the MHC class I heavy chain molecules can induce apoptosis in activated B-and T-cells (Genestier et al., 1997a; Wallen-Ohman et al., 1997) . Anti-human MHC class I antibodies were shown to induce apoptosis by a pathway that does not involve Fas (Apo-1, CD95)/Fasligand interaction (Genestier et al., 1997a,b; WallenOhman et al., 1997) . Some data suggest that this pathway involves activation of caspases upstream and downstream of ceramide production, leading to a reduction of mitochondrial transmembrane potential and subsequent transmission of the death signal (Woodle et al., 1997; Genestier et al., 1998) . It has been shown (Mori et al., 1999 ) that b 2 m induces apoptosis in several leukemia cell lines and that b 2 minduced apoptosis in the K562 chronic myelocytic leukemic cell line is not mediated through Fas/Fasligand or tumor necrosis factor-a (TNF-a)/TNF-a receptor systems. Moreover, a recent study (Fournel et al., 2000) demonstrated that the b 2 m-associated nonpolymorphic soluble HLA-G1 (sHLA-G1) isoform triggered Fas/Fas-ligand-mediated apoptosis in activating, but not resting, CD8
+ peripheral blood cells. We previously reported that the loss or decreased expression of b 2 m results in drug resistance in sublines of MCF-7 cells selected for resistance to the chemotherapeutic agent doxorubicin (DOX), and in a DOX-resistant variant of the T-47D human breast cancer cell line (Ogretmen et al., 1998) . These data suggested that the loss of b 2 m in cancer cells may cause both resistance to chemotherapy as well as an escape from immune surveillance. In this study, we (a) investigated whether the loss of b 2 m is associated with drug resistance in HL-60/ADR and HL-60/VCR cells compared to their parental drug-sensitive HL-60 human myelogenous leukemia cell line, (b) assessed whether adding b 2 m to growth media induces similar levels of apoptosis in these cells, and (c) probed the molecular mechanism of b 2 m-induced apoptosis in HL-60 cells and its drug resistant variants. Data presented in this report revealed that b 2 m induces caspasedependent release of cytochrome c in HL-60 and HL-60/VCR cells and indicate that a Z-VAD-fmk-sensitive caspase(s) which is not activated by caspases-3, -6, -8, or -9 is involved in b 2 -m-induced apoptosis in these cells. Moreover, b 2 m-induced apoptosis in HL-60/ADR cells is independent of Bax, and the activation of caspases-3, -6, -8, and -9, but rather occur through a Z-VAD-fmk-sensitive caspase(s) dierent from these caspases.
Results
Drug resistance characteristics and expression of MRP1, P-glycoprotein, Bcl-2, and Bax in HL-60, HL-60/ADR and HL-60/VCR cells The degrees of resistance to vincristine (VCR), vinblastine (VBL), and doxorubicin (DOX) in HL-60 cells, HL-60/ADR and HL-60/VCR variants were analysed by MTT assay. The concentration of each drug that reduced cell survival by 50% (IC 50 ) was determined from cell survival plots and the data are presented in Table 1 . Our results show that the MRPexpressing HL-60/ADR cells are about 122.5-, 14-and 8.5-fold more resistant to DOX, VCR and VBL, respectively, compared to their parental HL-60 cells (Table 1) . Moreover, HL-60/VCR cells expressed 3300-, 1400-, and 262-fold more resistance to VCR, VBL, and DOX, respectively (Table 1) . These results con®rm that HL-60/ADR and HL-60/VCR cells express resistance to a variety of chemotherapeutic agents consistent with the multidrug resistance (MDR) phenotype. Consistent with these drug resistance characteristics data, Western blot analysis ( Figure  1a ,b) using the monoclonal antibody QCRL1 speci®c for the multidrug resistance protein (MRP1) and monoclonal antibody C219 speci®c for P-glycoprotein (P-gp) con®rmed previous results (McGrath et al., 1989 , Krishnamachary et al., 1994 that HL-60/ADR and HL-60/VCR cells overexpress MRP1 and P-gp, respectively. Moreover, no MRP was detected in HL-60/VCR cells, and no P-gp was seen in HL-60/ADR cells (Figure 1a,b) . Furthermore, the data presented in Figure 1c clearly show that in addition to overexpression of P-gp in the HL-60/VCR cell line, the anti-apoptotic protein Bcl-2 is slightly overexpressed in this cell line compared to HL-60 cells. However, the expression level of the pro-apoptotic protein Bax remains the same in both HL-60 and HL-60/VCR cells (Figure 1d ). On the other hand, while the expression levels of Bcl-2 in HL-60 and HL-60/ADR cells are similar (Figure 1c) , Bax is totally lost in HL-60/ADR cells compared to HL-60 cells (Figure 1d ). Therefore, HL-60/VCR cells overexpress P-gp and Bcl-2, and HL-60/ADR cells overexpress MRP but have lost Bax during the development of the drug resistance phenotype.
Analysis of b 2 m expression in HL-60, HL-60/ADR and HL-60/VCR cells The protein levels of b 2 m in HL-60 and HL-60/ADR and HL-60/VCR cells were detected by two approaches: (a) immunoprecipitation of 35 S-methionine-labeled b 2 m using the mouse monoclonal antibody L368 speci®c for this protein, and (b) Western blotting using an anti-b 2 m rabbit polyclonal antibody (Figure 2a,b) . Figure 1a ,b To investigate whether caspases participate in b 2 minduced apoptosis, we treated HL-60, HL-60/ADR and HL-60/VCR cells in the absence or presence of 100 mM Z-VAD-fmk, an extremely ecient inhibitor of all caspases (Kunstle et al., 1997; Rodriguez et al., 1996) 3 h before treating the cells with 20 mg/ml b 2 m for 48 h. The results presented in Figure 7a ± c show that Z-VAD-fmk almost totally inhibited b 2 m-induced apoptosis in these three cell lines. Similar results were also seen by MTT assay (data not shown). These results suggest that b 2 m may induce apoptosis through the caspase cascade.
Cyclosporin A (CsA) is known to aect the mitochondria by inhibiting the mitochondrial permeability transition (MPT) pore, and therefore preventing disruption of the transmembrane potential (Nicolli et al., 1996; Halestrap et al., 1997) . To determine whether b 2 m-induced apoptosis is mediated by mitochonrial pathway of apoptosis, we exposed HL-60, HL-60/ADR and HL-60/VCR cells to 1 mM CsA for 30 min before treating the cells with 20 mg/ml b 2 m for 48 h. Data presented in Figure 7a ± c clearly show that while CsA did not aect b 2 m-induced apoptosis in HL-60 and HL-60/VCR cells, it abrogated apoptosis in HL-60/ ADR cells. These data and the results presented in Based on the results presented in Figure 7 , the general caspase inhibitor Z-VAD-fmk prevented b 2 minduced apoptosis in HL-60, HL-60/ADR and HL-60/ VCR cells. Therefore, to determine which speci®c caspases are activated in b 2 m-induced apoptosis, we performed Western blot analysis using antibodies to caspases-1, -3, -6, -8 and -9 in HL-60, HL-60/ADR and HL-60/VCR cells treated with 20 mg/ml b 2 m for 48 h. These antibodies recognize both the procaspases and the cleaved activated forms of these enzymes. Western blot analysis of caspase-1 revealed that an antibody to caspase-1 recognized a prominent 46 kDa protein, and it is under expressed in HL-60/ADR and HL-60/VCR cells ( Figure 9a ). However, b 2 m treatment did not induce proteolytic cleavage and activation of caspase-1 in HL-60 cells and its drug resistant variants ( Figure  9a ). Western blot analysis of caspase-3 showed that the anti-caspase-3 antibody recognized 32 kDa and 26 kDa protein species in HL-60, HL-60/ADR and HL-60/ VCR cells ( Figure 9b ). Moreover, treatment of these cells with 20 mg/ml b 2 m for 48 h did not cleave caspase-3 to its known 17 kDa active form ( Figure  9b ). Western blot analysis of caspase-6 showed the anti-caspase-3 antibody detected a 36 kDa and a 21 kDa protein species in the three cell lines. However, treatment of the cells with b 2 m did not cause processing and activation of the 36 kDa pro-caspase-6 to its active 12 kDa form ( Figure 9c ). Interestingly, Western blot analysis of caspase-8, presented in Figure  10a , showed that HL-60/ADR and HL-60/VCR cells under-express the 57 kDa pro-caspase-8 compared to HL-60 cells, but b 2 m treatment did not induce Figure 10b revealed that the antibody to this caspase predominantly recognizes the 46.5 kDa pro-caspase-9 also interacts with several minor proteins. As shown in Figure 10c , HL-60/VCR cells under-expressed procaspase-9 (Figure 10b ). However, treatment with 20 mg/ml b 2 m for 48 h did not induce cleavage of this enzyme to its active 35 and 37 kDa forms in HL-60 cells and its drug resistant variants (Figure 10b ). Poly (ADP-ribose) polymerase (PARP) is a 116 kDa nuclear enzyme that binds DNA strand breaks produced by various genotoxic agents, and it is implicated in conserving the integrity of the genome (Oliver et al., 1998; Decker et al., 2000) . This enzyme has therefore been shown as a caspase substrate, and cleavage of PARP from its 116 kDa to an 85 kDa form can be detected in caspase-dependent apoptosis induced by various stimuli (Nicholson and Thornberry, 1997; Decker et al., 2000) . To determine whether b 2 minduced apoptosis is associated with PARP cleavage, we used a rabbit polyclonal antibody produced to amino acids 764 ± 1014 located in the carboxy terminus of human PARP which recognizes both the 116 and 85 kDa forms of PARP. The data presented in Figure  10d clearly show that in HL-60, HL-60/ADR and HL-60/VCR cells treated with 20 mg/ml b 2 m for 48 h, PARP was not cleaved (Figure 10c ).
It has been reported that cathepsin B can cause apoptosis, and the general caspase inhibitor Z-VADfmk and inhibitors of caspases-1 and -3 also eectively inhibit cathepsin B activity and abrogate apoptosis induced by this non-caspase proteinase (Schotte et al., 1999) . Since the above results demonstrated that caspases-1, -3, -6, -8, and -9 were not involved in b 2 m-induced apoptosis, but that treating the cells with the general caspase inhibitor Z-VAD-fmk inhibited apoptosis, therefore, we explored the possibility that cathepsin B may be involved in apoptosis induced by b 2 m. In these experiments, we treated the cells with 100 mM Z-FA-fmk, a speci®c inhibitor of cathepsin B (Gregoli and Bondurant, 1999) , before cotreating with b 2 m as described in Materials and methods, and found that it did not aect b 2 m-induced apoptosis in HL-60 cells and its drug resistant variants.
The results presented above clearly revealed that b 2 m causes apoptosis in HL-60 and its MDR variants. The summary of these results in relation to caspasedependent and caspase-independent pathways of apoptotic cell death is presented in Figure 11 .
Discussion
The data presented in this study clearly demonstrated that adding exogenous b 2 m protein to the culture media causes apoptosis in HL-60 cells as well as in its drug resistant variants HL-60/ADR and HL-60/VCR nonspeci®c background¯uorescence as detected using an isotype-matched FITC-labeled control antibody and HL-60 cells. The black peaks on the right (a ± c) indicate b 2 m cell surface expression in HL-60 (A), HL-60/ADR (b), and HL-60/VCR (c) of the fraction analysed using the monoclonal antibody L368 and FITC-conjugated anti-mouse IgG. Similarly, the black peaks on the right (e ± g) indicate cell surface expression of heavy chain of MHC class I in HL-60 (e), HL-60/ADR (f), and HL-60/VCR (g) of the fraction analysed using an FITC-conjugated monoclonal antibody and anti-mouse IgG. Note that¯uorescence intensity is shown on a logarithmic scale (Mori et al., 1999; Wu et al., in preparation) , as well as in K562 leukemia-bearing mice via apoptosis induction (Mori et al., 2001) . These results suggest that b 2 m may utilize an apoptosis pathway distinct from Class I MHC antigen complexinduced apoptosis (Genestier et al., 1997a,b; WallenOhman et al., 1997) . The decreased expression levels of b 2 m in HL-60 drug resistant variants con®rms our previous report demonstrating that the loss of b 2 m expression in breast cancer cells is associated with resistance to DOX, and that inhibition of its expression in MCF-7 cells by an antisense b 2 m expression vector induced the drug resistance phenotype (Ogretmen et al., 1998) . Partial or complete loss of b 2 m in several aggressive metastatic cancers or cell lines derived from such cancers has been observed (Kakamanis et al., 1995; Vitale et al., 1998; Restifo et al., 1993; Benitez et al., 1998) . Moreover, the loss of b 2 m function caused by mutations in melanoma cells may be an early event in its progression to the malignant phenotype and is also associated with an unfavorable prognosis in gastrointestinal cancer (Yamamoto et al., 2001) . Restifo et al. (1996) have reported that b 2 mde®cient cells do not respond to speci®c T-cell therapy and that the loss of b 2 m may be a mechanism whereby tumor cells can acquire immunoresistance. Furthermore, b 2 m knockout NODE/SCID b 2 m null mice have reduced innate immunity (Christianson et al., 1997) , and human cord blood mononuclear stem cells repopulate 11-fold more when they are transplanted into these mice than in NODE/SCID mice because of their innate immunity (Kollet et al., 2000) .
Caspases play a central role in the execution of apoptosis and the most well studied pathways of caspase activation include the mitochondrion-initiated . In the mitochondrial pathway, cytochrome c, apoptosis-inducing factor (AIF) and other apoptosis-inducing factors are released from the intramembrane space to the cytosol (Liu et al., 1996; Susin et al., 1996) . Once released, cytochrome c, together with dATP, binds to apoptotic proteinase activating factor-1 (Apaf-1) and this complex, along with adenine nucleotides, promotes procaspase-9 autoactivation (Li et al., 1998) , which in turn activates caspases-2, -3, -6, -8 and -10 ( Slee et al., 1999 Slee et al., , 2001 Wolf and Green, 1999) . In the death receptor-mediated apoptosis pathway (Fas/Fas ligand interaction and cell death), caspase-8 is an initiator caspase that can activate the downstream caspases including caspase-3. Active caspase-8 also cleaves a pro-apoptotic Bcl-2 family member, Bid, and the truncated Bid induces mitochondrial cytochrome c release (Li et al., 1998; Luo et al., 1998) thereby linking the two pathways. After activation, both caspase-8 and caspase-9 activate caspase-3 which in turn cleaves other caspases and many cellular proteins Strasser et al., 2000) . Our results clearly showed that although b 2 m decreased Dcm in HL-60 and HL-60/VCR cells, it did not aect Dcm in HL-60/ADR cells. The use of DiOC 6 (3) for measuring mitochondrial Dcm is acceptable and has been used in many studies to correlate Dcm and apoptosis (Salvioli et al., 1997; Chen et al., 1988; Perkins et al., 2000) . It has been described that cytochrome c release can be induced by mitochondrial permeability transition characterized by loss of Dcm (Kroemer and Reed, 2000) . Consistent with these results, our results demonstrated that b 2 m induced signi®cant cytochrome c release from the mitochondria in HL-60 and HL-60/VCR cells but not in HL-60/ ADR cells. Moreover, the release of cytochrome c was caspase-dependent. The molecular mechanisms of the release of cytochrome c from the mitochondria are still unclear.
As shown by a number of investigations, Bax is involved in opening the MPT pore (Pastorino et al., 1999; Shimizu et al., 1999) , although others have not determined the importance of opening the MPT pore for Bax-induced cytochrome c release (Eskes et al., 1998; Finucane et al., 1999) . It is also known that CsA blocks the release of cytochrome c by blocking the MPT pore (Nicolli et al., 1996; Halestrap et al., 1997) . Due to the expression of P-gp or MRP1, the intracellular levels of CsA in these cells may vary. However, our data demonstrate that while CsA did not aect b 2 m-induced apoptosis in HL-60 and HL-60/ VCR cells, it inhibited apoptosis in HL-60/ADR cells, suggesting that b 2 m-induced apoptosis is not through MPT pore formation. Furthermore, b 2 m treatment did not aect the expression of the anti-apoptotic protein Bcl-2 in HL-60, HL-60/ADR and HL-60/VCR cells (Rastegar and Safa, unpublished results), indicating that cytochrome c release is not the result of decreased expression of this anti-apoptotic protein. Similarly, b 2 m treatment of these cells did not reduce expression of the heat shock protein 70 (data not shown), known to inhibit certain caspase-dependent and caspaseindependent apoptosis pathways (Creagh et al., 2000) . b 2 m-induced apoptosis in HL-60, HL-60/ADR and HL-60/VCR cells is also not mediated by p53 tumor suppressor protein since these cells do not express p53 (Takagi et al., 1999) .
Our data also demonstrate that treating the cells with Z-VAD-fmk, a general inhibitor of caspases /well in 96-well plates) were treated with or without 100 mM Z-VAD-fmk or 1 mM CsA for 3 h. After that, the treated cells were either grown in the presence of these agents or were exposed to 20 mg/ml b 2 m at 378C for 48 h, and apoptosis was quantitated by the Cell Death ELISA kit (Roche, Indianapolis, IN, USA). The A 405 readings obtained from ELISA were normalized for cell number and the results are expressed relative to HL-60, HL-60/ADR, and HL-60/VCR cells. Each point is the average of triplicate determinants. Error bars represent the standard deviation for each point. The results shown above are representative of three independent experiments Oncogene b 2 -microglobulin induced-apoptosis C-H Wu et al (Rodriguez et al., 1996; Kunstle et al., 1997) , abrogated b 2 m-induced apoptosis. However, Western blot analysis using antibodies to the post-mitochondrial caspases-3, -6 and -9, as well as caspases-1 and -8, which recognize both the pro-forms as well as activated forms of these caspases, revealed that none of these caspases are involved in b 2 m-induced apoptosis in HL-60, HL-60/ADR and HL-60/VCR cells. To con®rm our Western blot results that caspase-8 is not activated, we also performed Western blot analysis of the pro-apoptotic protein Bid in untreated and b 2 m-treated cells and found that all three cell lines contain full-length Bid, but were not able to detect degradation of the p15 form of truncated Bid (tBid) (Rastegar and Safa, unpublished results). Another line of evidence that caspases-3 and -8 are not involved in b 2 m-induced apoptosis in HL-60/VCR is that, as we have shown, these cells overexpress P-gp, and several reports showed that cells induced to overexpress P-gp either by drug selection or by gene transfer experiments are resistant to a variety of apoptotic stimuli including serum starvation, Fas ligand, tumor necrosis factor and UVirradiation (Robinson, et al., 1997; Bezombes, et al., 1998; Smyth, et al., 1998; Pallis and Russell, 2000) since caspases-3 and -8, but not caspase-9, activations are inhibited in P-gp expressing cells (Smyth et al., 1998; Ruepi et al., 2000) . Interestingly, P-gp cannot inhibit caspaseindependent apoptosis (Ruepi et al., 2000) . However, our Western blotting analysis revealed that b 2 m treatment did not induce activation of caspases-6 and -9 in HL-60 and its drug resistant variants, suggesting Z-VAD-fmk blocks b 2 m-induced apoptosis by targeting other known or unknown caspases or a non-caspase proteinase(s). Another strong evidence against caspase-3 involvement in b 2 m-induced apoptosis is that b 2 m did not induce proteolysis of PARP, a common caspase-3 substrate. Consistent with these results, Z-VAD-fmk-sensitive apoptosis induced by (7) or the cells treated with 50 mg/ml b 2 m (+) in the absence (7) or presence (+) of 100 mM Z-VAD-fmk (+) as described in Materials and methods. The same blot was probed with a mouse monoclonal antibody speci®c for b-actin to con®rm loading and transfer of the proteins (a ± f) aspirin also has been shown in the absence of PARP degradation (Castano et al., 1999) . Detailed molecular mechanisms of b 2 m-induced apoptosis remain to found. However, we have recently found that pre-treating HL-60, HL-60/ADR and HL-60/VCR cells with Fas or TNF-a receptor antibody prevented b 2 m-induced apoptosis, suggesting that the apoptosis is mediated through the Fas/Fas-ligand or tumor necrosis factor-a (TNF-a)/TNF-a receptor system (Wu and Safa, unpublished results). It is known that Fas ligand-and TNF-a-induced apoptosis are mediated through activation of caspase-8 (Boldin et al., 1996; Medema et al., 1997) and by caspase-independent pathways (Chang et al., 1998; Holler et al., 2000; Jones et al., 2000) . Our data showed that caspase-8 is not activated in b 2 m-induced apoptosis, suggesting the existence of a common apoptotic pathway for b 2 m, Fas or tumor TNF-a-mediated apoptosis independent of caspase-8 activation. Our results (Wu et al., unpublished results) and those reported by Mori et al. (1999) showed that b 2 m induces apoptosis in K562 cells and that pre-treating these cells with Fas or tumor TNF-a-antibodies did not prevent b 2 m-induced apoptosis. These cells are known to be Fas-de®cient (Munker et al., 1997) , but express TNF-a-receptors (Grazioli et al., 1994) . Mori et al. (1999) have suggested that the presence of a high molecular weight cell surface binding protein is presumably involved in b 2 m-induced apoptosis. Whether this surface protein is present in HL-60 cells and its drug resistant variants and whether it is indeed involved in b 2 m-induced apoptosis remain to be found. Moreover, adding exogenous b 2 m protein into the growth madia at 5 ± 10 mg/ml, near its physiological serum levels in human, results in a 2 ± 3-fold increase in DOX sensitivity in MCF-7 cells as well as in MCF-7 cells with partial loss of b 2 m due to transfection with an antisense b 2 m plasmid (Ogretmen et al., 1998) . Consistent with these results, transfection of these cells with a full-length cDNA clone expressing human b 2 m also resulted in increased sensitivity to DOX treatment to a level comparable to MCF-7 cells (Wu and Safa, unpublished data). b 2 m-induced sensitization of cells to DOX and the current work revealing that it causes apoptosis by itself suggest that two independent mechanisms may be involved. Enhanced sensitivity to DOX by b 2 m resembles that of TNF-a in which causes apoptosis by itself and at low-doses augments the anti-tumor activity of DOX (Ten Hagen et al., 2000) . b 2 m may not induce apoptosis in some cell lines and in contrast may cause a growth stimulatory eect. For example, b 2 m has been shown to be mitogenic to the PC-3 prostate carcinoma cell line and antagonistic to transforming growth factor b1 action (Rawley et al., 1995) . While the molecular mechanism of the lack of b 2 m-induced apoptosis in this cell line is unknown, these cells are also resistant to Fas-ligand or TNF-a (Chung et al., 1998; Takeuchi et al., 1996) .
In conclusion, for the ®rst time we have shown in this report that b 2 m can induce similar levels of apoptosis in HL-60 cells which are sensitive to cancer chemotherapeutic agents and in two MDR variants of this cell line (1) HL-60/VCR, which overexpresses P- Western blot analysis of caspases-1, -3, and -6, respectively was performed using aliquots of 1610 5 HL-60, HL-60/ADR and HL-60/VCR cells untreated (lanes 1, 3 and 5 in each blot) or treated with 20 mg/ml b 2 -m for 48 h at 378C (lanes 2, 4 and 6 in each blot) and anti-caspase-1, anti-caspase-3, or anti-caspase-6 antibodies as described in Materials and methods. The bottom portions of a and b are the same blots probed with a mouse monoclonal antibody speci®c for b-actin to con®rm equal loading and transfer of the proteins in each lane. Note that b 2 m did not induce cleavage and activation of these caspases Oncogene b 2 -microglobulin induced-apoptosis C-H Wu et al glycoprotein and Bcl-2, and (2) HL-60/ADR cells, overexpressing MRP1 but de®cient in Bax expression. We have demonstrated that (a) b 2 m activates an unknown Z-VAD-fmk sensitive caspase-dependent cell death pathway in HL-60 and HL-60/VCR cells that causes the release of cytochrome c independent of procaspase-8 activation, and mediates apoptotic events downstream of mitochondria but without activation of pro-caspase-8 and pro-caspase-9, and (b) b 2 m induces apoptosis in HL-60/ADR cells by a non-mitochondrial caspase pathway, and independently of Bax. Therefore, our results provide evidence that b 2 m is a proapoptotic factor and that it may use dierent signaling pathways to induce apoptotic cell death in drug sensitive and resistant cells with dierent mechanisms of resistance. Furthermore, understanding the molecular mechanisms of b 2 m-induced apoptosis in drug sensitive and resistant cells should provide insights and approaches useful for the development of more eective therapeutic strategies to eliminate cancer cells.
Materials and methods

Cell lines and culture conditions
The HL-60 human AML cell line and its MRP-mediated variant HL-60/ADR cell lines (McGrath et al., 1989) , and the MDR1-mediated multidrug resistant derivative HL-60/VCR (Ogretmen and Safa, 2000) were maintained in RPMI-1640 medium with 10% fetal calf serum (FCS) and 100 ng/ml each of penicillin and streptomycin (Life Technologies, Grand Island, NY, USA) at 378C in 5% CO 2 . HL-60/ADR and HL-60/VCR cells were grown in the presence of 1 mg/ml doxorubicin (DOX) and vincristine (VCR), respectively, which were removed from the media before performing experiments. Vincristine (VCR) and vinblastine (VBL) were obtained from Eli Lilly and Co. (Indianapolis, IN, USA) and doxorubicin (DOX) was purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Cell survival (MTT) assay
MTT assay was performed as previously described (Fleming et al., 1992) . Brie¯y, 1610 4 cells were plated in 100 ml of the growth medium in the presence or absence of increasing concentrations of chemotherapeutic drugs or b 2 m, or 10 mg/ ml anti-b 2 m-monoclonal antibody L368 in 96-well plates and cultured at 378C in 5% CO 2 for 48 h. The cells were then incubated with 25 ml of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT, 5 mg/ml) at 378C for 4 h. After dissolving the crystals with 0.04 N HCl in isopropanol, plates were read in a microplate reader (Dynatech Lab Inc., Chantilly, VA, USA) at 570 nm. The concentration of drug that inhibited cell survival by 50% (IC 50 ) was determined from cell survival plots. The anti-b 2 m monoclonal antibody 
Immunoprecipitations
The expression level of b 2 -m was determined by immunoprecipitation analysis as we described previously (Ogretmen and Safa, 1997) . In short, the cells (about 5610 5 ) were incubated in 2 ml methionine-free growth media containing 50 mCi [ 35 S]methionine for 18 h at 378C. Following PBS washes, the cells were resuspended in lysis buer (142.5 mM KCl, 5 mM MgCl 2 , 10 mM HEPES, 1 mM EGTA, 0.2 % IGEPAL, 2 mM PMSF, and 1 mg/ml leupeptin) and frozen at 7808C. Following 35 S-methionine labeling, equal TCA counts of the lysates (1610 6 c.p.m.) were used for immunoprecipitations. After the lysates were precleared with 50 ml protein Gagarose (Life Technologies), they were incubated with 20 mg of the mouse anti-b 2 m monoclonal antibody L368 for 1 h at 48C. The immunocomplexes were then precipitated using protein G-agarose for 1 h at 48C. The agarose beads were washed two times with washing buer containing 50 mM Tris-base, 150 mM NaCl (TBS), 1 mM EDTA, 1% deoxycholate, 1% Triton-X100, 0.1% SDS, and 1 mM PMSF, then two times with 50 mM TBS to remove nonspeci®c binding. The immune complexes were then resuspended in equal volumes of SDS-sample buer and analysed by SDS ± PAGE followed by¯uorography as described. The immunoprecipitated proteins were detected by autoradiography.
Western blot analysis
Western blot analysis was performed as we described elsewhere (Ogretmen and Safa, 1997) Figure 11 Signaling pathways of apoptotic cell death and involvement of b 2 m in apoptosis. Caspase-dependent apoptotic cell death induced by mitochondrial pathway is caused by disruption of mitochondrial membrane potential (Dcm), release of cytochrome c, activation of caspase-9, and subsequent activation of downstream caspases-2, -3, 6, -7, -8 and -10, which eventually leads to apoptosis. Caspase-dependent apoptosis induced by death receptor ligation (e.g., Fas ligand/Fas, or TNFa/TNFa receptor) can function independent of the mitochondria and is inhibited by P-gp at the level of caspase-8 and -3 activation. Caspase-8 activation also can cause proteolytic cleavage of the pro-apoptotic protein Bid to a truncated form (tBid), which in turn is inserted in the mitochondrial membrane and induce release of cytochrome c. Moreover, disruption of Dcm results in release of AIF which can cause caspase-independent apoptosis. Data presented in this report revealed that b 2 m-induces caspase-dependent release of cytochrome c in HL-60, and HL-60/VCR cells and indicate that a Z-VAD-fmk-sensitive caspase(s) which is not activated by caspases-3, 6, -8 and -9 is involved in b 2 m-induced apoptosis in these cells (these events are shown in bold). Moreover, b 2 m-induced apoptosis in HL-60/ADR cells is independent of mitochondria, activation of caspases-3, -6, -7, -8 and -9, but rather occurs through a Z-VAD-fmk-sensitive caspase(s) dierent from these caspases Oncogene b 2 -microglobulin induced-apoptosis C-H Wu et al antibody (1 : 1000 w/v), as well as the anti-cytochrome c antibody (1 : 1000 w/v) were purchased from BD Pharmingen (San Diego, CA, USA). The anti-caspase-8 monoclonal antibody 1C12 (1 : 100 w/v) and anti-caspase 9 polyclonal antibody (1 : 1000 v/v) were purchased from Cell Signaling Technology (Beverly, MA, USA). In short, 5610 5 cells or 50 mg protein/lane were separated by 5 ± 15% SDS ± PAGE containing 6.5 M urea, blotted onto a PDVF Immobilon membrane, and then the protein levels were detected using dilutions of the antibodies stated above and the peroxidaseconjugated secondary anti-rabbit, anti-mouse or anti-goat antibodies (1 : 2500 v/v) (Amersham, Arlington Heights, IL, USA). The proteins were visualized using the ECL protein detection kit (Amersham, Arlington Heights, IL, USA) as described by manufacturer. The membranes were then exposed to Kodak X-Omat ®lm for various times. Equal loading was con®rmed by Coomassie blue staining of SDS ± PAGE strips cut from gels containing 80 mg protein/lane of each sample prior to blotting.
RNA isolation and RT ± PCR
b 2 m mRNA levels were analysed by PT ± PCR. In short, total RNA from HL-60 and HL-60/ADR cells were isolated using Tri Reagent TR-118 (Molecular Research Center, Cincinnati, OH, USA) as described by manufacturer. One mg of total RNA was used in reverse transcription reactions with M-MLV reverse transcriptase and oligo (dT)15 primer (Promega, Madison, WI, USA) as described by the manufacturer. The resulting cDNA was then used as the template in PCR to measure the b 2 m mRNA levels. The intactness of total RNA was con®rmed by tight bands of 28S and 18S rRNA separated on denaturing agarose gels and visualized by ethidium bromide staining. The b 2 m primers were designed according to the sequence published (Gussow et al., 1987) . The primers of PCR were as follows: b 2 m forward 5'-GGCAGGATCCGAGATGTCTCGCTCCGTGGC (26 ± 55); b 2 m reverse 5'-AAACCTCGAGGATGCTGCTTA-CATGTCTCG (385 ± 416); b-actin forward 5'-CAGAGCAA-GAGAGGCATCCT (216 ± 235); b-actin reverse 5'-TTGAAGGTCTCAAACATGAT (405 ± 424). The reactions were performed using Tag DNA polymerase at 948C for denaturation, 588C for annealing and 728C for extension for 30 cycles. The b-actin mRNA levels were used as internal controls. The ampli®ed fragments were separated on 1.5% agarose gels and visualized by ethidium bromide staining. The intensity of RT ± PCR products on agarose gels were quantitated by densitometer.
Flow cytometric analysis of b 2 m and HLA1
HL-60, HL-60/ADR and HL-60/VCR cells (5610 6 ) from the culture media were spun down at 5006g and resuspended in 200 ml PBS. Twenty ml of b 2 m monoclonal antibody L368 or anti-HLA1 FITC conjugated monoclonal antibody (Sigma, St. Louis, MO, USA) were added to the cell suspension and incubated for 30 min on ice. Mouse IgG 2a was used as the control antibody for both. For b 2 m analysis, after washing the cells with PBS, FITC-conjugated anti-mouse IgG (Fc speci®c; Sigma, St. Louis, MO, USA) was added in a 1 : 32 dilution for another 30 min on ice. Following rinsing, the samples were analysed with¯ow cytometric quantitation using a FACSCalibur¯ow cytometer (Becton Dickinson, San Jose, CA, USA). The data were quantitated using the Cell Quest program.
Detection of apoptosis
DNA fragmentation due to apoptotic cell death in HL-60 cells was quantitated by detecting cytoplasmic DNA-histone complexes using the Cell Death ELISA kit (Roche, Indianapolis, IN, USA). Cells were incubated with or without various concentrations of b 2 m for 48 h at 378C, and apoptosis was measured by Cell Death ELISA assay as described by manufacturer. In short, 1610 4 HL-60 cells were suspended in 200 ml lysis buer and incubated for 30 min at RT. After centrifugation, 20 ml supernatant were transferred to the streptavidin-coated microtiter plate (MTP) and then 80 ml of immunoreagent were added to each well followed by incubation and shaking for 2 h at RT. After rinsing, ABTS substrate was added and the color development for photometric analysis was measured at 405 nm against ABTS solution as a blank by a MRX ELISA reader (Dynatech Lab Inc., Chantilly, VA, USA). To determine whether caspases are involved in apoptosis induced by b 2 m, the general caspase inhibitor, Z-VAD-fmk (benzyloxycarbonyl-Val-Ala-Asp¯uor-omethylketone) (CalBiochem, San Diego, CA, USA) was dissolved in dimethylsulfoxide (DMSO; Sigma, St. Louis, MO, USA) and used. The ®nal concentration of DMSO is 0.1%. Cells (1610 4 ) were incubated in the presence or absence of 100 M Z-VAD-fmk for 3 h at 378C, then treated with or without 20 or 50 mg b 2 m and processed for Cell Death ELISA assay as described above. To determine whether mitochondria and cytochrome c were involved in the apoptotic cascade, 1 mM cyclosporin A (Sigma, St. Louis, MO, USA) was added 30 min prior to b 2 m. To access the eect of the cathepsin B inhibitor, on the apoptosis, cells were co-treated with 1 mg/ml Z-FA-fmk and 20 mg/ml b 2 m for 48 h.
Cytofluorimetric analysis of mitochondrial Dcm
Variations of mitochondrial transmembrane potential Dcm during apoptosis in HL-60, HL-60/ADR and HL-60/VCR cells were studied using 3,3'-dihexyloxacarbocyanine (DiOC 6 (3); Molecular Probes, Inc., Eugene, OR, USA). This dye accumulates in the mitochondrial matrix under the in¯uence of the Dcm (Chen et al., 1988) . Cells were treated with or without 50 mg b 2 m in culture media for 48 h. Subsequently, 5610 5 of the cells were incubated in 200 ml of PBS containing 0.1 mM of DiOC 6 (3) for 30 min. DiOC 6 (3) membrane potential-related¯uorescence was recorded using FL1 photomultiplier tube (PMT) by a FACSCalibur¯ow cytometer. For each analysis, 1610 4 cells were analysed.
Preparation of cytosol fractions from HL60 cells and detection of cytochrome c HL-60 cells ( 1610 7 ) were incubated with or without 20 or 50 mg b 2 m for 48 h. The cells were then harvested by centrifugation at 1800 g for 10 min at 48C. After being washed once with ice-cold phosphate buered saline (PBS), the cell pellet was suspended in 56 volume of ice-cold buer A (20 mM HEPES-KOH [pH 7.5], 10 mM KCl, 1.5 mM MgCl 2 , 1 mM sodium EDTA, 1 mM sodium EGTA, 1 mM dithiothreitol [DTT] , and 0.1 mM PMSF), supplemented with protease inhibitors (5 mg/ml pepstatin A, 10 mg/ml leupeptin, 2 mg/ml aprotinin) and containing 250 mM sucrose. After leaving the cells on ice for 15 min, they were disrupted by douncing in a 5 ml homogenizer. After centrifugation in a microcentrifuge for 5 min at 48C, the supernatants were further centrifuged at 10 5 g for 30 min in a tabletop airfuge (Beckman). The resulting supernatants were subjected to SDS ± PAGE and transferred to a PVDF Immobilon membrane, which was then used for Western blotting either with an anti-cytochrome c antibody (BD Pharmingen, San Diego, CA, USA) or with an anti-b-actin antibody (Sigma, St. Louis, MO, USA).
